美国42个州和城市孕产妇死亡评审中可预防性评估的洞察
本研究对美国40个州和2个城市的孕产妇死亡评审委员会最新公开数据进行二次分析,评估妊娠相关死亡和妊娠相关死亡的预防可能性及影响因素。结果显示,2010年后发生的妊娠相关死亡中可预防比例为53%至93.8%,妊娠相关死亡中为45%至100%。作者认为需重新评估预防性评估的定义、结构和输出,以更好地指导州和国家项目与政策。
要点
- 2010年后妊娠相关死亡中可预防比例为53%至93.8%,妊娠相关死亡中为45%至100%。
- 10个州报告妊娠相关死亡按死因预防性:子痫前期-子痫和心理健康状况>90%可预防。
- 14个州报告739例妊娠相关死亡中描述3345个影响因素;20个委员会数据中37.7%妊娠相关死亡涉及种族主义或歧视。
核心结论
- 美国大部分妊娠相关死亡和妊娠相关死亡是可预防的,但各州对可预防死亡比例和影响因素识别存在广泛差异。
- 需重新评估目前多数孕产妇死亡评审委员会采用的孕产妇死亡可预防性评估的定义、结构和输出,以充分指导州和国家项目与政策。
研究设计与样本
- 本研究是对美国40个州和2个城市最新公开的孕产妇死亡评审委员会数据的二次分析,数据基于横断面、人群为基础的资料。
- 在妊娠期间或产后1年内因任何原因死亡(妊娠相关死亡)以及因妊娠或其管理相关原因(非意外原因)死亡(妊娠相关死亡)中分析可预防性。
- 按死因和影响因素(社区、患者-家庭、提供者、机构、卫生系统因素)探索可预防性。
主要发现
- 2010年后发生的死亡中,42个州和城市妊娠相关死亡可预防比例为53%至93.8%,妊娠相关死亡为45%至100%。
- 10个州报告妊娠相关死亡按死因可预防性:子痫前期-子痫和心理健康状况死亡>90%可预防,出血和心血管状况>80%可预防,感染和血栓栓塞约70%可预防,羊水栓塞和卒中约40%可预防。
- 14个州的孕产妇死亡评审委员会报告描述了与739例妊娠相关死亡相关的3345个影响因素。
- 患者-家庭和提供者因素合计最常被提及与妊娠相关死亡相关,但各州间这些因素的贡献分别在6%至56%和18%至42.3%之间变化。
- 基于20个有可用信息的孕产妇死亡评审委员会数据,37.7%的妊娠相关死亡涉及种族主义或歧视。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The rising trend in maternal mortality over the past 3 decades sets the United States apart from all other high-income countries. Multidisciplinary state and city Maternal Mortality Review Committees conduct comprehensive reviews of maternal deaths, including assessments of preventability and contributing factors. OBJECTIVE: Assess preventability of and contributing factors to maternal mortality in the U.S. STUDY DESIGN: This study is a secondary analysis of cross-sectional, population-based data from the most recent, publicly available Maternal Mortality Review Committee data from 40 state and 2 cities in the U.S. Preventability were analyzed among all deaths during pregnancy or within 1 year postpartum from any cause (pregnancy-associated deaths) and deaths during pregnancy or within 1 year postpartum from causes related to pregnancy or its management, but not from accidental causes (pregnancy-related deaths). We also explored preventability by cause-of-death and contributing factors grouped as community, patient-family, provider, facility, and health system factors. RESULTS: Of deaths that occurred after 2010, between 53% to 93.8% of pregnancy-associated deaths and 45% to 100% of pregnancy-related deaths were deemed preventable across the 42 states and cities. Across the 10 states reporting pregnancy-related death preventability by cause-of-death, Maternal Mortality Review Committees deemed preventable >90% of deaths from preeclampsia-eclampsia and mental health conditions, >80% of deaths from hemorrhage and cardiovascular conditions, about 70% of deaths from infection and thrombotic embolism, and about 40% of deaths from amniotic fluid embolism and stroke. A total of 3345 contributing factors were described in Maternal Mortality Review Committee reports from 14 states in relation to 739 pregnancy-related deaths. While collectively patient-family and provider factors were most frequently noted as contributing to pregnancy-related deaths, the contribution of such factors varied between 6% to 56% and 18% to 42.3%, respectively, across the states. Based on data from 20 Maternal Mortality Review Committees with available information, racism or discrimination were noted in relation to 37.7% of pregnancy-related deaths. CONCLUSION: A large proportion of pregnancy-associated deaths and pregnancy-related deaths in the U.S. are preventable. However, likely due to differences in Maternal Mortality Review Committee membership, available data, and judgement employed to determine preventability, wide variation exists in the proportion of deaths deemed preventable and factors identified as contributing to such deaths across states. There is need to reevaluate the definitions, structure, and outputs for maternal death preventability assessments currently employed by a majority Maternal Mortality Review Committees to adequately inform state and national programming and policies.
引用
- Qian J, Wolfson C, Kramer B, et al. Insights from preventability assessments across 42 state and city maternal mortality reviews in the United States. Am J Obstet Gynecol. 2024. PMID: 39197563. doi:10.1016/j.ajog.2024.08.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。